O	0	10	Randomised
O	10	11	,
O	12	17	phase
O	18	20	II
O	20	21	,
O	22	29	placebo
O	29	30	-
O	30	40	controlled
O	40	41	,
O	42	47	trial
O	48	50	of
B-intervention	51	62	fulvestrant
I-intervention	63	67	plus
I-intervention	68	78	vandetanib
O	79	81	in
O	82	96	postmenopausal
O	97	102	women
O	103	107	with
O	108	112	bone
O	113	117	only
O	118	120	or
O	121	125	bone
O	126	137	predominant
O	137	138	,
O	139	146	hormone
O	146	147	-
O	147	155	receptor
O	155	156	-
O	156	164	positive
O	165	175	metastatic
O	176	182	breast
O	183	189	cancer
O	190	191	(
O	191	194	MBC
O	194	195	)
O	195	196	:
O	197	200	the
O	201	205	OCOG
O	206	214	ZAMBONEY
O	215	220	study
O	220	221	.

O	222	232	Biomarkers
O	233	235	of
O	236	240	bone
O	241	249	turnover
O	249	250	,
O	251	260	including
O	261	266	urine
O	267	268	N
O	268	269	-
O	269	280	telopeptide
O	281	282	(
O	282	286	uNTx
O	286	287	)
O	287	288	,
O	289	293	have
O	294	298	been
O	299	303	used
O	304	306	as
O	307	316	surrogate
O	317	325	measures
O	326	328	of
O	329	337	response
O	338	340	to
O	341	345	bone
O	345	346	-
O	346	354	targeted
O	355	364	therapies
O	364	365	.

O	366	374	Vascular
O	375	386	endothelial
O	387	393	growth
O	394	400	factor
O	401	402	(
O	402	406	VEGF
O	406	407	)
O	408	414	levels
O	415	424	correlate
O	425	429	with
O	430	436	extent
O	437	439	of
O	440	444	bone
O	445	455	metastases
O	455	456	.

O	457	459	We
O	460	468	assessed
O	469	476	whether
O	477	487	vandetanib
O	487	488	,
O	489	491	an
O	492	501	inhibitor
O	502	504	of
O	505	509	VEGF
O	509	510	,
O	511	520	epidermal
O	521	527	growth
O	528	534	factor
O	535	543	receptor
O	544	547	and
O	548	551	RET
O	552	562	signalling
O	562	563	,
O	564	572	improved
O	573	577	uNTx
O	578	586	response
O	587	591	when
O	592	597	added
O	598	600	to
O	601	612	fulvestrant
O	613	614	(
O	614	615	F
O	615	616	)
O	617	619	in
O	620	626	breast
O	627	633	cancer
O	634	642	patients
O	643	647	with
O	648	652	bone
O	653	663	metastases
O	663	664	.

B-eligibility	665	679	Postmenopausal
I-eligibility	680	688	patients
I-eligibility	689	693	with
I-eligibility	694	698	bone
I-eligibility	699	710	predominant
I-eligibility	710	711	,
I-eligibility	712	719	hormone
I-eligibility	719	720	-
I-eligibility	720	728	receptor
I-eligibility	728	729	-
I-eligibility	729	737	positive
I-eligibility	738	748	metastatic
I-eligibility	749	755	breast
I-eligibility	756	762	cancer
O	763	767	were
O	768	778	randomised
O	779	781	to
O	782	783	F
O	784	785	(
O	785	788	500
O	789	791	mg
O	792	794	IM
O	795	799	days
O	800	801	1
O	801	802	,
O	803	805	15
O	805	806	,
O	807	809	29
O	809	810	,
O	811	815	then
O	816	823	monthly
O	823	824	)
O	825	829	with
O	830	836	either
O	837	847	vandetanib
O	848	849	(
O	849	852	100
O	853	855	mg
O	856	858	PO
O	859	861	OD
O	861	862	)
O	863	864	(
O	864	866	FV
O	866	867	)
O	868	870	or
B-control	871	878	placebo
I-control	879	880	(
I-control	880	882	FP
I-control	882	883	)
O	883	884	.

O	885	888	The
O	889	896	primary
O	897	906	objective
O	907	910	was
B-outcome-Measure	911	915	uNTx
I-outcome-Measure	916	924	response
O	924	925	.

O	926	935	Secondary
O	936	946	objectives
O	947	955	included
B-outcome-Measure	956	959	PFS
O	959	960	,
B-outcome-Measure	961	963	OS
O	963	964	,
B-outcome-Measure	965	971	RECIST
I-outcome-Measure	972	980	response
O	980	981	,
B-outcome-Measure	982	986	pain
I-outcome-Measure	987	993	scores
O	994	997	and
B-outcome-Measure	998	1006	toxicity
O	1006	1007	.

B-intervention-participants	1008	1013	Sixty
I-intervention-participants	1013	1014	-
I-intervention-participants	1014	1017	one
O	1018	1026	patients
O	1027	1031	were
O	1032	1041	allocated
O	1042	1044	to
O	1045	1047	FV
O	1048	1051	and
B-control-participants	1052	1054	68
O	1055	1057	to
O	1058	1060	FP
O	1060	1061	.

O	1062	1065	Out
O	1066	1068	of
B-total-participants	1069	1072	127
O	1073	1083	analyzable
O	1084	1092	patients
O	1092	1093	,
O	1094	1096	an
B-outcome	1097	1101	uNTx
I-outcome	1102	1110	response
O	1111	1119	occurred
O	1120	1122	in
B-iv-bin-percent	1123	1125	66
I-iv-bin-percent	1126	1127	%
O	1128	1131	for
O	1132	1134	FV
O	1135	1138	and
B-cv-bin-percent	1139	1141	54
I-cv-bin-percent	1142	1143	%
O	1144	1147	for
O	1148	1150	FP
O	1151	1152	(
O	1152	1153	p
O	1154	1155	=
O	1156	1157	0
O	1157	1158	.
O	1158	1160	21
O	1160	1161	)
O	1161	1162	.

O	1163	1165	No
O	1166	1176	difference
O	1177	1180	was
O	1181	1189	detected
O	1190	1197	between
O	1198	1204	groups
O	1205	1208	for
B-outcome	1209	1212	PFS
O	1212	1213	;
O	1214	1216	HR
O	1217	1218	=
O	1219	1220	0
O	1220	1221	.
O	1221	1223	95
O	1224	1225	(
O	1225	1227	95
O	1228	1229	%
O	1230	1232	CI
O	1233	1234	0
O	1234	1235	.
O	1235	1237	65
O	1237	1238	-
O	1238	1239	1
O	1239	1240	.
O	1240	1242	38
O	1242	1243	)
O	1244	1246	or
B-outcome	1247	1249	OS
O	1250	1252	HR
O	1253	1254	=
O	1255	1256	0
O	1256	1257	.
O	1257	1259	69
O	1260	1261	(
O	1261	1263	95
O	1264	1265	%
O	1266	1268	CI
O	1269	1270	0
O	1270	1271	.
O	1271	1273	37
O	1273	1274	-
O	1274	1275	1
O	1275	1276	.
O	1276	1278	31
O	1278	1279	)
O	1279	1280	.

O	1281	1284	For
O	1285	1288	the
O	1289	1291	62
O	1292	1300	patients
O	1301	1305	with
O	1306	1316	measurable
O	1317	1324	disease
O	1324	1325	,
B-outcome	1326	1334	clinical
I-outcome	1335	1342	benefit
I-outcome	1343	1348	rates
O	1349	1353	were
B-iv-bin-percent	1354	1356	41
O	1357	1360	and
B-cv-bin-percent	1361	1363	43
I-cv-bin-percent	1364	1365	%
O	1365	1366	,
O	1367	1379	respectively
O	1380	1381	(
O	1381	1382	p
O	1383	1384	=
O	1385	1386	0
O	1386	1387	.
O	1387	1389	47
O	1389	1390	)
O	1390	1391	.

B-outcome	1392	1399	Serious
I-outcome	1400	1407	adverse
I-outcome	1408	1414	events
O	1415	1419	were
O	1420	1427	similar
O	1427	1428	,
B-iv-bin-percent	1429	1430	3
I-iv-bin-percent	1430	1431	.
I-iv-bin-percent	1431	1432	3
I-iv-bin-percent	1433	1434	%
O	1435	1438	for
O	1439	1441	FV
O	1442	1448	versus
B-cv-bin-percent	1449	1450	5
I-cv-bin-percent	1450	1451	.
I-cv-bin-percent	1451	1452	9
I-cv-bin-percent	1453	1454	%
O	1455	1458	for
O	1459	1461	FP
O	1461	1462	.

O	1463	1471	Elevated
O	1472	1480	baseline
O	1481	1485	uNTx
O	1486	1487	(
O	1487	1488	>
O	1488	1490	65
O	1491	1493	nM
O	1494	1497	BCE
O	1497	1498	/
O	1498	1502	mmol
O	1503	1505	Cr
O	1505	1506	)
O	1507	1510	was
O	1511	1521	prognostic
O	1522	1525	for
B-outcome	1526	1529	PFS
O	1529	1530	,
O	1531	1533	HR
O	1534	1535	=
O	1536	1537	1
O	1537	1538	.
O	1538	1540	55
O	1541	1542	(
O	1542	1544	95
O	1545	1546	%
O	1547	1549	CI
O	1550	1551	1
O	1551	1552	.
O	1552	1554	04
O	1554	1555	-
O	1555	1556	2
O	1556	1557	.
O	1557	1559	30
O	1559	1560	)
O	1561	1564	and
O	1565	1568	for
B-outcome	1569	1571	OS
O	1571	1572	,
O	1573	1575	HR
O	1576	1577	=
O	1578	1579	2
O	1579	1580	.
O	1580	1582	32
O	1583	1584	(
O	1584	1586	95
O	1587	1588	%
O	1589	1591	CI
O	1592	1593	1
O	1593	1594	.
O	1594	1596	25
O	1596	1597	-
O	1597	1598	4
O	1598	1599	.
O	1599	1601	33
O	1601	1602	)
O	1602	1603	.

O	1604	1607	The
O	1608	1616	addition
O	1617	1619	of
O	1620	1630	vandetanib
O	1631	1633	to
O	1634	1645	fulvestrant
O	1646	1649	did
O	1650	1653	not
O	1654	1661	improve
O	1662	1671	biomarker
O	1672	1680	response
O	1680	1681	,
O	1682	1685	PFS
O	1686	1688	or
O	1689	1691	OS
O	1692	1694	in
O	1695	1703	patients
O	1704	1708	with
O	1709	1713	bone
O	1714	1724	metastases
O	1724	1725	.

O	1726	1734	Baseline
O	1735	1739	bone
O	1740	1748	turnover
O	1749	1752	was
O	1753	1763	prognostic
O	1764	1767	for
O	1768	1771	PFS
O	1772	1775	and
O	1776	1778	OS
O	1778	1779	.
